While clinical and preclinical studies present conflicting results with some studies suggesting that GLP‐1 RAs have no increased risk of breast cancer and others pointing to potential tumor‐promoting effects, there is a critical need for future prospective trials. This evidence concerns the gene GCG and breast cancer.